Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8207416 | 1.00 | USP2 (0.61) | USP2SLCO1B1LMNAL3MBTL1TDP1 | |
| SCHEMBL13189917 | 0.94 | USP2 (0.52) | USP2SLCO1B1LMNAL3MBTL1TDP1 | |
| SCHEMBL3431986 | 0.80 | USP2 (0.57) | USP2SLCO1B1LMNAL3MBTL1TDP1 | |
| SCHEMBL9549501 | 0.80 | USP2 (0.57) | USP2SLCO1B1LMNAL3MBTL1TDP1 | |
| SCHEMBL1080339 | 0.79 | USP2 (0.55) | USP2SLCO1B1LMNAL3MBTL1TDP1 | |
| SCHEMBL9818719 | 0.78 | PDE4A (0.58) | USP2SLCO1B1LMNAL3MBTL1TDP1 | |
| SCHEMBL28085169 | 0.78 | PDE4A (0.58) | USP2SLCO1B1LMNAL3MBTL1TDP1 | |
| SCHEMBL2937201 | 0.78 | PDE4A (0.58) | USP2SLCO1B1LMNAL3MBTL1TDP1 | |
| SCHEMBL13189918 | 0.78 | USP2 (0.32) | USP2SLCO1B1 | |
| SCHEMBL18177455 | 0.77 | PDE4A (0.56) | USP2SLCO1B1LMNAL3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118146277-A | GalNAc compound containing 1,2, 3-triazole structure and conjugation method of GalNAc compound and oligonucleotide | 北京悦康科创医药科技股份有限公司 | 2024-06-07 | — | — | CN | claimed |
| EP-4328310-A1 | SIRNA TARGETING 17B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 AND SIRNA CONJUGATE | Tuojie Biotech (Shanghai) Co., Ltd. (CN) | 2024-02-28 | — | — | EP | claimed |
| WO-2023205606-A1 | COMPOSITIONS AND METHODS FOR ENHANCING AAV THERAPY AND DECREASING TROPISM OF AAV TO THE LIVER | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-26 | — | — | WO | claimed |
| WO-2021064614-A1 | TOLL-LIKE RECEPTOR 7 AND/OR 8 AGONISTS AND USES THEREOF | Janssen Biopharma, Inc. (US) | 2021-04-08 | — | — | WO | claimed |
| EP-2651420-A2 | PEPTIDE-BASED IN VIVO SIRNA DELIVERY SYSTEM | Arrowhead Research Corporation (US) | 2013-10-23 | — | — | EP | claimed |
| WO-2012083185-A2 | PEPTIDE-BASED IN VIVO SIRNA DELIVERY SYSTEM | ARROWHEAD RESEARCH CORPORATIONS (US) | 2012-06-21 | — | — | WO | claimed |
| CN-118146277-A | GalNAc compound containing 1,2, 3-triazole structure and conjugation method of GalNAc compound and oligonucleotide | 北京悦康科创医药科技股份有限公司 | 2024-06-07 | — | — | CN | disclosed |
| WO-2024100044-A1 | POLYPLEXES OF NUCLEIC ACIDS AND TARGETED CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL | TARGIMMUNE THERAPEUTICS AG (CH) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024100046-A1 | TARGETED LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | TARGIMMUNE THERAPEUTICS AG (CH) | 2024-05-16 | — | — | WO | disclosed |
| EP-4214316-A2 | METHODS FOR THE REDUCTION OF Z-AAT PROTEIN LEVELS | Arrowhead Pharmaceuticals, Inc. (US) | 2023-07-26 | — | — | EP | disclosed |
| WO-2023079142-A2 | TARGETED LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | TARGIMMUNE THERAPEUTICS AG (CH) | 2023-05-11 | — | — | WO | disclosed |
| WO-2022060721-A2 | METHODS FOR THE REDUCTION OF Z-AAT PROTEIN LEVELS | Arrowhead Pharmaceuticals, Inc. (US) | 2022-03-24 | — | — | WO | disclosed |
| WO-2021064614-A1 | TOLL-LIKE RECEPTOR 7 AND/OR 8 AGONISTS AND USES THEREOF | Janssen Biopharma, Inc. (US) | 2021-04-08 | — | — | WO | disclosed |
| WO-2017027350-A2 | RNAI THERAPY FOR HEPATITIS B VIRUS INFECTION | Arrowhead Pharmaceuticals, Inc. (US) | 2017-02-16 | — | — | WO | disclosed |
| EP-3060664-A1 | MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY | Regulus Therapeutics Inc. (US) | 2016-08-31 | — | — | EP | disclosed |
| EP-2992096-A1 | COMPOUNDS AND METHODS FOR ENHANCED CELLULAR UPTAKE | Regulus Therapeutics Inc (US) | 2016-03-09 | — | — | EP | disclosed |
| WO-2015173208-A9 | OLIGOMERS AND OLIGOMER CONJUGATES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-12-30 | — | — | WO | disclosed |
| WO-2015173208-A2 | OLIGOMERS AND OLIGOMER CONJUGATES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-11-19 | — | — | WO | disclosed |
| WO-2015061536-A1 | MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY | Regulus Therapeutics Inc. (US) | 2015-04-30 | — | — | WO | disclosed |
| WO-2014179445-A1 | COMPOUNDS AND METHODS FOR ENHANCED CELLULAR UPTAKE | Regulus Therapeutics Inc. (US) | 2014-11-06 | — | — | WO | disclosed |